168 related articles for article (PubMed ID: 34597666)
1. BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.
Ishii Y; Kolluri KK; Pennycuick A; Zhang X; Nigro E; Alrifai D; Borg E; Falzon M; Shah K; Kumar N; Janes SM
J Biol Chem; 2021 Nov; 297(5):101223. PubMed ID: 34597666
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
3. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.
Baritaki S; Katsman A; Chatterjee D; Yeung KC; Spandidos DA; Bonavida B
J Immunol; 2007 Oct; 179(8):5441-53. PubMed ID: 17911631
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.
Huerta-Yepez S; Vega M; Escoto-Chavez SE; Murdock B; Sakai T; Baritaki S; Bonavida B
Nitric Oxide; 2009 Feb; 20(1):39-52. PubMed ID: 18778787
[TBL] [Abstract][Full Text] [Related]
6. Alterations in
Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression.
Yu H; Mashtalir N; Daou S; Hammond-Martel I; Ross J; Sui G; Hart GW; Rauscher FJ; Drobetsky E; Milot E; Shi Y; Affar el B
Mol Cell Biol; 2010 Nov; 30(21):5071-85. PubMed ID: 20805357
[TBL] [Abstract][Full Text] [Related]
8. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
Kolluri KK; Alifrangis C; Kumar N; Ishii Y; Price S; Michaut M; Williams S; Barthorpe S; Lightfoot H; Busacca S; Sharkey A; Yuan Z; Sage EK; Vallath S; Le Quesne J; Tice DA; Alrifai D; von Karstedt S; Montinaro A; Guppy N; Waller DA; Nakas A; Good R; Holmes A; Walczak H; Fennell DA; Garnett M; Iorio F; Wessels L; McDermott U; Janes SM
Elife; 2018 Jan; 7():. PubMed ID: 29345617
[TBL] [Abstract][Full Text] [Related]
9. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract][Full Text] [Related]
10. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
[TBL] [Abstract][Full Text] [Related]
11. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
De Rienzo A; Chirieac LR; Hung YP; Severson DT; Freyaldenhoven S; Gustafson CE; Dao NT; Meyerovitz CV; Oster ME; Jensen RV; Yeap BY; Bueno R; Richards WG
J Pathol; 2021 Jan; 253(1):68-79. PubMed ID: 32944962
[TBL] [Abstract][Full Text] [Related]
12. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
13. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Sacco JJ; Kenyani J; Butt Z; Carter R; Chew HY; Cheeseman LP; Darling S; Denny M; Urbé S; Clague MJ; Coulson JM
Oncotarget; 2015 May; 6(15):13757-71. PubMed ID: 25970771
[TBL] [Abstract][Full Text] [Related]
14. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
Pasello G; Urso L; Silic-Benussi M; Schiavon M; Cavallari I; Marulli G; Nannini N; Rea F; Ciminale V; Favaretto A
J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
[TBL] [Abstract][Full Text] [Related]
16. Targeting BAP1: a new paradigm for mesothelioma.
Schunselaar LM; Zwart W; Baas P
Lung Cancer; 2017 Jul; 109():145-146. PubMed ID: 28342657
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of diffuse malignant peritoneal mesothelioma.
Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract][Full Text] [Related]
19. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
Bruno R; Alì G; Poma AM; Proietti A; Libener R; Mariani N; Niccoli C; Chella A; Ribechini A; Grosso F; Fontanini G
J Mol Diagn; 2020 Apr; 22(4):457-466. PubMed ID: 32036091
[TBL] [Abstract][Full Text] [Related]
20. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]